SCHEMBL1225940

SCHEMBL1225940

N#Cc1cccc(/C=C/C(=O)O)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
P4HB P07237 14/20 0.64
NPSR1 Q6W5P4 1/20 0.57
MAOA P21397 2/20 0.57
MAOB P27338 2/20 0.57
FBP1 P09467 1/20 0.55
HDAC3 O15379 1/20 0.55
TNKS O95271 1/20 0.55
HDAC4 P56524 1/20 0.55
HDAC1 Q13547 1/20 0.55
HCAR2 Q8TDS4 1/20 0.55
HDAC7 Q8WUI4 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC8 Q9BY41 1/20 0.55
TNKS2 Q9H2K2 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
HDAC9 Q9UKV0 1/20 0.55
HDAC5 Q9UQL6 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30912094 1.00 P4HB (0.64) P4HBNPSR1MAOAMAOBFBP1
SCHEMBL1225943 1.00 P4HB (0.64) P4HBNPSR1MAOAMAOBFBP1
SCHEMBL30745014 1.00 P4HB (0.64) P4HBNPSR1MAOAMAOBFBP1
Hydrochloric Acid SCHEMBL4101473 0.98 P4HB (0.62) P4HBNPSR1MAOAMAOBFBP1
SCHEMBL8497675 0.88 P4HB (0.66) P4HBMAOAMAOBFBP1
SCHEMBL7339707 0.88 P4HB (0.66) P4HBMAOAMAOBFBP1
SCHEMBL9168215 0.87 P4HB (0.56) P4HBNPSR1MAOAMAOB
SCHEMBL9168213 0.87 P4HB (0.56) P4HBNPSR1MAOAMAOB
SCHEMBL8148520 0.85 P4HB (0.62) P4HBMAOAMAOBFBP1
SCHEMBL4101470 0.85 P4HB (0.62) P4HBMAOAMAOBFBP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111295382-B Bridged bicyclic compounds as farnesyl ester X receptor modulators 百时美施贵宝公司 2024-02-02 CN disclosed
EP-3470407-B1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2024-01-24 EP disclosed
US-11872202-B2 Pleuromutilin cinnamic acid ester compounds with activities against antibiotic-resistant infections SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2024-01-16 US disclosed
EP-3704113-B1 BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS BRISTOL MYERS SQUIBB CO (US) 2023-10-11 EP disclosed
US-20230172889-A1 PLEUROMUTILIN CINNAMIC ACID ESTER COMPOUNDS WITH ACTIVITIES AGAINST ANTIBIOTIC-RESISTANT INFECTIONS SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2023-06-08 US disclosed
CN-114230519-A Pleuromutilin cinnamate compounds with drug-resistant bacterium resisting activity and synthesis method and application thereof 陕西科技大学 2022-03-25 CN disclosed
CN-110248971-B Copolymer and optical film using the same 东曹株式会社 2021-11-02 CN disclosed
US-10953007-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2021-03-23 US disclosed
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-08-04 US disclosed
CN-111295382-A Bridged bicyclic compounds as modulators of farnesoid X receptors 百时美施贵宝公司 2020-06-16 CN disclosed
US-4845110-A Organic compounds and their pharmaceutical use LILLY INDUSTRIES LIMITED (GB) 1989-07-04 US disclosed
EP-0134111-B1 ARALIPHATIC SULPHIDES,SULPHONES AND SULPHOXIDES AND THEIR PHARMACEUTICAL USE Lilly Industries Limited (GB) 1988-12-07 EP disclosed
EP-0235452-A2 Organic compounds and their pharmaceutical use LILLY INDUSTRIES LIMITED (GB) 1987-09-09 EP disclosed
US-4665189-A LEUKOTRIENE ANTAGONISTS LILLY INDUSTRIES LIMITED (GB) 1987-05-12 US disclosed
EP-0201823-A2 Novel intermediates for the production of pharmaceuticals LILLY INDUSTRIES LIMITED (GB) 1986-11-20 EP disclosed
EP-0186426-A2 Tetrazolyl compounds and their pharmaceutical use Lilly Industries Limited (GB) 1986-07-02 EP disclosed
EP-0134111-A1 Araliphatic sulphides,sulphones and sulphoxides and their pharmaceutical use Lilly Industries Limited (GB) 1985-03-13 EP disclosed
EP-0052921-B1 METHODS AND COMPOSITIONS FOR ASSAYING FOR THE PRODUCTION OF 1,4-DIHYDROPYRIDYL SYVA COMPANY (US) 1984-06-13 EP disclosed
US-4404278-A RADIOIMMUNOLOGY; FLUORESCENCE; ANTIBODIES SYVA COMPANY (US) 1983-09-13 US disclosed
EP-0052921-A1 Methods and compositions for assaying for the production of 1,4-dihydropyridyl SYVA COMPANY (US) 1982-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10953007-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPM6 P4HB 2561/4885NPSR1 241/4885MAOA 1453/4885
US-20230172889-A1 PLEUROMUTILIN CINNAMIC ACID ESTER COMPOUNDS WITH ACTIVITIES AGAINST ANTIBIOTIC-RESISTANT INFECTIONS RELA, PLEC, ABL1 P4HB 420/4885NPSR1 1945/4885MAOA 3399/4885
US-10730863-B2 Bridged bicyclic compounds as farnesoid X receptor modulators NR1H4, FXR1, NR1H2 P4HB 2276/4885NPSR1 570/4885MAOA 4098/4885
US-11872202-B2 Pleuromutilin cinnamic acid ester compounds with activities against antibiotic-resistant infections RELA, PLEC, ABL1 P4HB 420/4885NPSR1 1945/4885MAOA 3399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.